Intelligence
Pricing

Materials

BioLargo Reports Q3 2025 Financial and Operational Progress

Author:
FAQSIR News Desk
Last Updated:
Reading Time
2 min

#BioLargo Releases Q3 2025 Financial Results

BioLargo, Inc. (OTCQX:BLGO), a firm specializing in sustainable technologies aimed at addressing environmental challenges, announced its financial and operational results for the third quarter of 2025. The report reflects the company's performance for the three and nine months ending September 30, 2025.

#Financial Highlights

For the third quarter, BioLargo reported revenues of $1.21 million, contributing to a year-to-date total of $7.26 million. The decline in revenue compared to the previous year was primarily due to diminished sales from the Pooph-branded pet odor elimination product, which was affected by licensing issues.

As of September 30, 2025, the company maintained a robust financial position, concluding the quarter with a cash balance of $4.5 million and no toxic debt. The total assets stood at $9.24 million against liabilities of $5.92 million, resulting in stockholders' equity of approximately $3.32 million.

#Operational Progress and Future Prospects

In a quarterly earnings call held on November 14, Dennis P. Calvert, BioLargo’s President and CEO, expressed optimism about the company's growth trajectory. Significant advancements have been made in various product lines, including the upcoming launches of the wound care and surgical product lines and the notable progress in PFAS treatment technology, which is nearing the commencement of a commercial demonstration.

Additionally, the Cellinity™ battery platform is being developed as a potentially transformative solution for grid-scale energy storage, with ongoing efforts to secure partnerships for necessary capital to advance commercialization.

BioLargo has also filed a nine-count lawsuit against Pooph Inc. The legal action is intended to protect the company's intellectual property rights and facilitate collaboration with partners who align with its values of quality and transparency. The company does not anticipate that this lawsuit will adversely affect other business units or initiatives.

#Key Takeaways

  • BioLargo reported Q3 2025 revenues of $1.21 million, totaling $7.26 million year-to-date.
  • The company has a cash balance of $4.5 million and no toxic debt, maintaining a solid financial footing.
  • Progress continues in technology sectors, with significant upcoming launches in wound care and PFAS treatment products.
  • The CEO remains optimistic about future collaborations and commercial growth despite ongoing legal issues with Pooph Inc.

Original source: Read original article

Frequently Asked Questions

In Q3 2025, BioLargo reported revenues of $1.21 million, with year-to-date revenues at $7.25 million. Though there was a decline year-on-year due to reduced sales from the Pooph-branded product, the overall financial health remains solid with a cash balance of $4.5 million and no toxic debt.
BioLargo has filed a nine-count federal lawsuit against Pooph Inc. to protect its intellectual property. This legal action is poised to safeguard its interests and allow the company to collaborate with partners who align with its values, thus aiming to mitigate any negative impacts on other business units.
The company has made significant strides in its technology portfolio, particularly in areas such as wound care and surgical product lines nearing launch, and notable progress with its PFAS treatment technology, which is preparing for a commercial demonstration.
BioLargo is optimistic about its future commercialisation efforts, especially with the upcoming launches of its wound care and surgical products, and ongoing developments in its Cellinity™ battery platform, which holds promise for grid-scale energy storage.
BioLargo has maintained a strong financial footing, with a healthy cash balance, no toxic debt, and a solid asset base. This positions the company well for future growth and the pursuit of new opportunities across various industries.
The company is actively working with prospective factory partners to secure capital necessary for the commercialisation of its innovative technologies, indicating a proactive approach to funding its growth initiatives.
BioLargo acknowledges potential risks, including economic conditions affecting consumer purchasing decisions and the competitive landscape. However, these risks are paralleled with the company’s capacity to innovate and respond to market demands effectively.
Additional details regarding BioLargo's innovative environmental technologies can be found on their official website, providing insights into their solutions for pressing environmental and cleantech challenges.